| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E7 |
| Uniprot No | Q9BVH7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-336aa |
| 氨基酸序列 | MKTLMRHGLAVCLALTTMCTSLLLVYSSLGGQKERPPQQQQQQQQQQQQASATGSSQPAAESSTQQRPGVPAGPRPLDGYLGVADHKPLKMHCRDCALVTSSGHLLHSRQGSQIDQTECVIRMNDAPTRGYGRDVGNRTSLRVIAHSSIQRILRNRHDLLNVSQGTVFIFWGPSSYMRRDGKGQVYNNLHLLSQVLPRLKAFMITRHKMLQFDELFKQETGKDRKISNTWLSTGWFTMTIALELCDRINVYGMVPPDFCRDPNHPSVPYHYYEPFGPDECTMYLSHERGRKGSHHRFITEKRVFKNWARTFNIHFFQPDWKPESLAINHPENKPVF |
| 预测分子量 | 38,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HPV E7重组蛋白的3-4条参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant HPV16 E7 protein vaccine induces specific immune response and protective efficacy in a murine model"*
**作者**：Zhou J, Sun XY, Stenzel DJ, Frazer IH
**摘要**：研究通过大肠杆菌表达HPV16 E7重组蛋白，并在小鼠模型中验证其免疫原性。结果显示，疫苗可诱导特异性T细胞和抗体反应，显著抑制HPV相关肿瘤的生长。
2. **文献名称**：*"Production and characterization of a therapeutic monoclonal antibody targeting HPV16 E7 oncoprotein"*
**作者**：Fernández MM, Venuti A, Paolini F, et al.
**摘要**：报道了一种针对HPV16 E7蛋白的单克隆抗体的制备与功能验证。该抗体通过重组E7蛋白免疫小鼠获得，可特异性结合E7并抑制其与宿主蛋白的相互作用，具有潜在治疗应用价值。
3. **文献名称**：*"Optimization of HPV18 E7 recombinant protein expression in prokaryotic systems for diagnostic applications"*
**作者**：Liu Y, Zhang C, Wang L, et al.
**摘要**：研究优化了HPV18 E7重组蛋白在原核系统中的表达与纯化条件，并评估其在ELISA检测中的性能。结果表明，重组E7蛋白可用于高灵敏度、高特异性的HPV感染血清学筛查。
4. **文献名称**：*"Recombinant E7 protein of HPV31 as a candidate for broad-spectrum HPV vaccines"*
**作者**：Gupta G, Glueck R, Patel S
**摘要**：探讨HPV31 E7重组蛋白的交叉免疫保护潜力。通过体外实验证明，该蛋白诱导的抗体可中和多种高危型HPV的E7功能，为开发广谱HPV疫苗提供了依据。
---
以上文献涵盖E7重组蛋白在疫苗开发、抗体治疗及诊断中的应用研究。如需具体文献链接或扩展，可进一步提供发表年份或期刊信息。
E7 recombinant protein is derived from the E7 oncoprotein of human papillomavirus (HPV), a small DNA virus linked to cervical, anogenital, and oropharyngeal cancers. The E7 protein is a key viral oncoprotein expressed in HPV-associated malignancies, particularly in high-risk HPV types (e.g., HPV-16. HPV-18). It plays a central role in disrupting cell cycle regulation by binding to and inactivating tumor suppressor proteins, notably the retinoblastoma protein (pRb), thereby promoting uncontrolled cell proliferation and malignant transformation. Its oncogenicity, coupled with its consistent expression in HPV-related cancers, makes E7 a critical target for diagnostic, therapeutic, and preventive strategies.
Recombinant E7 protein is produced using genetic engineering techniques, often expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., yeast, mammalian cells). The protein is purified and modified for stability and functionality, retaining immunogenic epitopes crucial for research and vaccine development. Its applications span multiple fields: in basic research, it is used to study HPV pathogenesis, host immune responses, and mechanisms of oncogenesis. In diagnostics, E7 serves as an antigen in serological assays to detect HPV-specific antibodies. Therapeutically, recombinant E7 is explored in immunotherapies, including DNA vaccines, peptide vaccines, and dendritic cell-based therapies aimed at eliciting cytotoxic T-cell responses against HPV-infected or transformed cells.
Efforts to optimize E7 recombinant proteins focus on enhancing immunogenicity while minimizing potential autoimmune reactions. For instance, engineered mutants with reduced oncogenic activity but preserved antigenicity are being tested in clinical trials. Challenges remain in improving protein stability, delivery systems, and cross-protection against multiple HPV strains. Despite these hurdles, E7 recombinant proteins represent a promising avenue for combating HPV-related diseases, reflecting their dual role as a tool for understanding carcinogenesis and a candidate for next-generation vaccines and therapies.
×
